dc.contributor.author | Rush, HL | |
dc.contributor.author | Murphy, L | |
dc.contributor.author | Morgans, AK | |
dc.contributor.author | Clarke, NW | |
dc.contributor.author | Cook, AD | |
dc.contributor.author | Attard, G | |
dc.contributor.author | Macnair, A | |
dc.contributor.author | Dearnaley, DP | |
dc.contributor.author | Parker, CC | |
dc.contributor.author | Russell, JM | |
dc.contributor.author | Gillessen, S | |
dc.contributor.author | Matheson, D | |
dc.contributor.author | Millman, R | |
dc.contributor.author | Brawley, CD | |
dc.contributor.author | Pugh, C | |
dc.contributor.author | Tanguay, JS | |
dc.contributor.author | Jones, RJ | |
dc.contributor.author | Wagstaff, J | |
dc.contributor.author | Rudman, S | |
dc.contributor.author | O'Sullivan, JM | |
dc.contributor.author | Gale, J | |
dc.contributor.author | Birtle, A | |
dc.contributor.author | Protheroe, A | |
dc.contributor.author | Gray, E | |
dc.contributor.author | Perna, C | |
dc.contributor.author | Tolan, S | |
dc.contributor.author | McPhail, N | |
dc.contributor.author | Malik, ZI | |
dc.contributor.author | Vengalil, S | |
dc.contributor.author | Fackrell, D | |
dc.contributor.author | Hoskin, P | |
dc.contributor.author | Sydes, MR | |
dc.contributor.author | Chowdhury, S | |
dc.contributor.author | Gilbert, DC | |
dc.contributor.author | Parmar, MKB | |
dc.contributor.author | James, ND | |
dc.contributor.author | Langley, RE | |
dc.date.accessioned | 2022-02-03T11:22:41Z | |
dc.date.available | 2022-02-03T11:22:41Z | |
dc.date.issued | 2022-03-10 | |
dc.identifier.citation | Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, pp. JCO2100728 - ? | |
dc.identifier.issn | 0732-183X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4997 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.doi | 10.1200/jco.21.00728 | |
dc.identifier.doi | 10.1200/jco.21.00728 | |
dc.description.abstract | PURPOSE: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data may guide treatment choices. METHODS: A group of patients within the STAMPEDE trial were contemporaneously enrolled with the possibility of being randomly allocated to receive either docetaxel + SOC or AAP + SOC. A mixed-model assessed QOL in those who had completed at least one QLQ-C30 + PR25 questionnaire. The primary outcome measure was difference in global-QOL (QLQ-C30 Q29&30) between patients allocated to docetaxel + SOC or AAP + SOC over the 2 years after random assignment, with a predefined criterion for clinically meaningful difference of > 4.0 points. Secondary outcome measures included longitudinal comparison of functional domains, pain, and fatigue, plus global-QOL at defined timepoints. RESULTS: Five hundred fifteen patients (173 docetaxel + SOC and 342 AAP + SOC) were included. Baseline characteristics, proportion of missing data, and mean baseline global-QOL scores (docetaxel + SOC 77.8 and AAP + SOC 78.0) were similar. Over the 2 years following random assignment, the mean modeled global-QOL score was +3.9 points (95% CI, +0.5 to +7.2; P = .022) higher in patients allocated to AAP + SOC. Global-QOL was higher for patients allocated to AAP + SOC over the first year (+5.7 points, 95% CI, +3.0 to +8.5; P < .001), particularly at 12 (+7.0 points, 95% CI, +3.0 to +11.0; P = .001) and 24 weeks (+8.3 points, 95% CI, +4.0 to +12.6; P < .001). CONCLUSION: Patient-reported QOL was superior for patients allocated to receive AAP + SOC, compared with docetaxel + SOC over a 2-year period, narrowly missing the predefined value for clinical significance. Patients receiving AAP + SOC reported clinically meaningful higher global-QOL scores throughout the first year following random assignment. | |
dc.format | Print-Electronic | |
dc.format.extent | JCO2100728 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
dc.title | Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-10-01 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1200/jco.21.00728 | |
rioxxterms.licenseref.startdate | 2021-11-10 | |
dc.relation.isPartOf | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Academic Radiotherapy (Dearnaley) | |
icr.researchteam | Prostate and Bladder Cancer Research | |
dc.contributor.icrauthor | Dearnaley, David | |
dc.contributor.icrauthor | James, Nicholas | |